MacroGenics
Clinical trials sponsored by MacroGenics, explained in plain language.
Biopharmaceutical company developing antibody-based cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New Antibody-Drug conjugate targets Hard-to-Treat cancers Results expected Nov 2026 (estimated)
- New hope for tough blood cancers: experimental drug MGD024 enters human testing Results expected Nov 2026 (estimated)
- New drug lorigerlimab takes on Platinum-Resistant ovarian cancer Results expected Jul 2027 (estimated)
-
New drug MGC026 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…
Phase 1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug lorigerlimab takes on Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis phase 2 trial is testing a drug called lorigerlimab in about 80 people with advanced ovarian or clear cell gynecologic cancers that have stopped responding to platinum chemotherapy. Lorigerlimab is a bispecific antibody designed to activate the immune system against tumors. …
Phase 2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests MGC028, a drug that delivers a cancer-killing agent directly to tumor cells. About 124 adults with advanced lung, bile duct, pancreatic, or colorectal cancers that have stopped responding to standard treatments will receive the drug every three weeks.…
Phase 1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC